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1594Decreased Serum Albumin as a Biomarker for
Severe Acute Graft-versus-Host Disease after
Reduced-Intensity Allogeneic Hematopoietic
Cell Transplantation
Andrew R. Rezvani, Barry E. Storer, Rainer F. Storb, Marco Mielcarek,
David G. Maloney, Brenda M. Sandmaier, Paul J. Martin, George B. McDonaldBiomarkers capable of predicting the onset and severity of acute graft-versus-host disease (aGVHD) after
allogeneic hematopoietic cell transplantation (HCT) would enable preemptive and risk-stratified therapy. Se-
vere aGVHD leads to gastrointestinal protein loss, resulting in hypoalbuminemia. We hypothesized that de-
creases in serum albumin at onset of aGVHD would predict the risk of progression to severe aGVHD. We
identified 401 patients who developed aGVHD grades II-IV after reduced-intensity allogeneic HCT and re-
viewed all available serum albumin values from 30 days before HCT to 45 days after initiation of treatment
for aGVHD. A $0.5 g/dL decrease in serum albumin concentration from pretransplantation baseline to the
onset of treatment for aGVHD predicted the subsequent development of grade III/IV aGVHD (versus grade
II aGVHD) with a sensitivity of 69% and a specificity of 73%. Overall mortality at 6 months after initiation of
aGVHD treatment was 36% versus 17% for patients with and without$0.5 g/dL decreases in serum albumin,
respectively (P 5 .0009). We conclude that change in serum albumin concentration from baseline to
initiation of aGVHD treatment is an inexpensive, readily available, and predictive biomarker of GVHD
severity and mortality after reduced-intensity allogeneic HCT.
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Acute graft-versus-host disease (aGVHD) is a fre-
quent complication of allogeneic hematopoietic cell
transplantation (HCT), affecting the skin, liver, and
gastrointestinal tract and contributing to transplant-
related morbidity and mortality. Approximately 50%
to 60% of patients require systemic treatment for
aGVHD after allogeneic HCT [1]. Treatment of
aGVHD is effective in most patients, but approxi-
mately 5% to 15% develop severe and therapy-Clinical Research Division, Fred Hutchinson Cancer
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Because most patients with aGVHD respond well to
existing treatments, measures that prospectively iden-
tify the small group destined to develop severe
aGVHDmight be more useful than global intensifica-
tion of aGVHD prophylaxis or treatment. Biomarkers
capable of predicting both the clinical onset and the ul-
timate severity of aGVHD before treatment initiation
would enable preemptive and risk-stratified therapy.
Numerous biomarkers for aGVHD have been
proposed and described in the transplant literature,
although none has yet entered clinical practice. An
ideal biomarker would be predictive of both disease
onset and prognosis, inexpensive, consistent across
laboratories, and readily available with a rapid turn-
around time to facilitate real-time clinical decision
making. Investigators in Genoa, Italy, have described
a prognostic score based on the clinical characteristics
and a combination of standard serum chemistries
measured at day 17 after HCT [2,3]. Specific
cytokines and proteins, such as tumor necrosis
factor-alpha, transforming growth factor-beta, solu-
ble IL-2 receptor, Fas, and vascular endothelial
Table 1. Characteristics of 401 Patients with aGVHDGrades
II-IV after Reduced-Intensity Allogeneic HCT
Age at HCT, years
Median (range) 55 (<1-75)
Gender
Male 254 (63%)
Female 147 (37%)
Donor
Related donor 164 (41%)
Unrelated donor 237 (59%)
HLA-matched 173
HLA-mismatched 64
Transplant indication
Acute myeloid leukemia 104
Non-Hodgkin lymphoma 77
Multiple myeloma 56
Chronic lymphocytic leukemia 39
Myelodysplastic syndrome 25
Primary ID/marrow failure 25
Acute lymphoblastic leukemia 24
Hodgkin’s lymphoma 23
Chronic myelogenous leukemia 11
Aplastic anemia 7
Solid tumor 6
Myeloproliferative disorder 4
Conditioning regimen
2 Gy TBI 51
2 Gy TBI + fludarabine 90 mg/m2 320
3 Gy TBI + fludarabine 90 mg/m2 14
4 Gy TBI + fludarabine 90 mg/m2 7
CY 200 mg/kg + hATG 90 mg/kg 8
No conditioning 1
Stem cell source
G-PBMC 370 (92%)
Bone marrow 31 (8%)
CD34+ cell dose, cells/kg
Median 7.82  106
Median time to aGVHD onset 35 days
Peak aGVHD grade
II 325 (81%)
III-IV 76 (19%)
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tive value as aGVHD biomarkers when assayed
individually [4]. More recently, investigators have
applied proteomic approaches to develop panels of
predictive biomarkers, with several groups reporting
promising initial findings [5-8]. Although proteomic
approaches are invaluable in discovering novel
markers of aGVHD, the operating characteristics of
putative biomarkers have not yet yielded clinically
useful assays with adequate positive and negative
predictive value in population-based studies.
Since the advent of ursodiol prophylaxis, liver
aGVHD has become rare, and midgut involvement is
now predominantly responsible for the morbidity
and mortality associated with aGVHD [9]. Protein
loss through the gut is characteristic of midgut
aGVHD [10]. We hypothesized that intestinal protein
loss in patients destined to develop clinical aGVHD
would be reflected by a decrease in serum albumin.
Because intestinal protein loss in aGVHD precedes
the development of mucosal erosion, ulceration, and
denudation, we further hypothesized that changes in
serum albumin concentration would allow early iden-
tification of patients whose aGVHD would be charac-
terized bymidgut injury and a poor prognosis. Because
conditioning chemoradiotherapy may also cause mu-
cosal injury and protein loss, we limited our analysis
to patients conditioned with reduced-intensity regi-
mens that produce minimal regimen-related gut toxic-
ity, thus isolating the relationship between aGVHD
and gastrointestinal protein loss.aGVHD indicates acute graft-versus-host disease; HCT, hematopoietic
cell transplantation; HLA, human leukocyte antigen; ID, immunodefi-
ciency; TBI, total body irradiation; CY, cyclophosphamide; hATG, horse
antithymocyte globulin; G-PBMC, granulocyte colony-stimulating factor-
mobilized peripheral blood mononuclear cells.PATIENTS AND METHODS
Patient Selection
We retrospectively reviewed the records of 708
consecutive patients who received a first allogeneic
HCT after reduced-intensity conditioning according
to Fred Hutchinson Cancer Research Center institu-
tional research protocols between December 16,
1997, and April 29, 2009. One of the investigators
(P.J.M.) reviewed the clinical course of all patients
and determined the date of initiation of systemic treat-
ment for aGVHD and the peak stage and grade of
aGVHD. These determinations were completed be-
fore, and independently of, the analysis described
here.Techniques of HCT
Patients and their respective donors were tested for
HLA-A,HLA-B, andHLA-C by at least intermediate-
resolution DNA typing and for HLA-DRB1 and
HLA-DQB1 by high-resolution techniques. Condi-
tioning regimens included low-dose total body irradi-
ation (TBI) of 2 to 4 Gy with or without fludarabine90 mg/m2 in 392 patients (98%) and cyclophospha-
mide 200 mg/kg with horse antithymocyte globulin
90 mg/kg in 8 patients (2%). One patient received no
conditioning (Table 1). Supportive care, including
antimicrobial and cytomegalovirus prophylaxis, was
administered as described previously [11]. Postgrafting
immunosuppression consisted of cyclosporine or ta-
crolimus combined with mycophenolate mofetil, as
previously described [12-14]. Seventeen patients also
received sirolimus as GVHD prophylaxis [14]. Hema-
topoietic growth factors were administered to the re-
cipient only for persistent neutropenia after day 121.
First-line treatment for aGVHD consisted of cortico-
steroids at 1 to 2 mg/kg [15], whereas second-line and
subsequent therapies (if needed) were prescribed at
the discretion of the attending physician, subject to
available institutional research protocols. Exogenous
albumin was not routinely administered, and was
used only as a supportive measure in cases of large-
volume paracentesis.
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Serum albumin levels were assayed at least once
before HCT, at least once per week during the first
3 months after HCT, and more frequently as clini-
cally indicated, per institutional standard practice.
We reviewed all available serum albumin values
from 30 days before HCT to 45 days after initiation
of treatment for aGVHD. Serum albumin was mea-
sured by clinical laboratories at the University of
Washington Medical Center, the Seattle Cancer
Care Alliance, and Seattle Children’s Hospital using
SYNCHRON Systems machines and bichromatic
digital endpoint methodology with bromcresol purple
reagent.
Statistical Analysis
Baseline albumin was defined as the minimum
albumin value measured within 30 days before HCT.
Albumin at the onset of GVHD treatment was defined
as the highest albumin value occurring within 2 days of
the start of treatment. Overall survival (OS) was esti-
mated by the Kaplan-Meier method, and cumulative
incidents of nonrelapse mortality (NRM) and relapse
were calculated according to methods previously
described [16]. All deaths occurring in the absence of
documented relapsed malignancy were considered
NRM. Cox regression models were used to estimate
hazard ratios. Relapses that occurred before the onset
of treatment were accommodated in these analyses by
assigning the day of relapse to the first day after treat-
ment. Receiver-operating characteristic (ROC) curves
and associated parameters were derived from logistic
regression models. Initial models used albumin at the
start of GVHD therapy or the change in albumin
from baseline as single predictors. Subsequent models
added HLA-matching (HLA-matched versus HLA-
mismatched), donor relation (related versus unre-
lated), time to onset of aGVHD, patient age, and total
serum bilirubin, blood urea nitrogen, creatinine, and
platelet count at the initiation of aGVHD therapy.
The latter 6 variables were entered as continuous
variables; creatinine and bilirubin were truncated at
a maximum value of 5.0.Figure 1. Change in absolute (A) and relative (B) serum albumin con-
centration in patients with peak grade 2 aGVHD (solid line) versus peak
grade 3/4 aGVHD (dashed line). Albumin concentration (ordinate) is in
grams per deciliter.RESULTS
Of 708 consecutive transplant recipients, 401
(57%) developed aGVHD grades II-IV requiring sys-
temic treatment and were included in this analysis
(Table 1). In these 401 patients with aGVHD grades
II-IV, aGVHD peaked at grade II in 325 patients
(81%) and grades III-IV in the remaining 76 patients
(19%). Most patients had HLA-matched donors,
whereas 16% hadHLA-mismatched unrelated donors.
The majority of patients (371, 93%) were conditioned
with 2 Gy TBI with or without fludarabine. Mobilizedperipheral blood mononuclear cell grafts were used in
370 patients (92%), whereas the remaining 31 patients
(8%) received bone marrow grafts. Patients initiated
systemic treatment for aGVHD at a median of
35 days after HCT (range: 5-175 days). Three hundred
fifty-two patients (88%) had sufficient albumin data
available to calculate both a baseline value (between
day230 and day21 before HCT) and a value at treat-
ment initiation (within 2 days before or after initiation
of systemic treatment for aGVHD).Serum Albumin Concentration and Severity of
aGVHD
Before the initiation of treatment for aGVHD,
patients whose aGVHD was ultimately graded as
III/IV showed sharp decreases in mean serum albumin
concentrations, both in absolute terms and relative
to pretransplantation baseline albumin concentrations
(Figure 1). This decrease from baseline first became
apparent approximately 5 days before starting systemic
treatment for aGVHD. In contrast, patients whose
aGVHD never exceeded grade II showed no change
from baseline in mean serum albumin concentration.
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treatment initiation for aGVHD, a decrease in serum
albumin concentration of $0.5 g/dL from baseline
optimally discriminated between patients who subse-
quently developed severe aGVHD and those whose
aGVHD peaked at grade II, with an area under the
ROC curve of 0.76 (Figure 2). A decrease from base-
line serum albumin concentration of $0.5 g/dL at
the time of treatment initiation predicted progression
to severe aGVHDwith a sensitivity of 69% and a spec-
ificity of 73%, with reference to those patients whose
aGVHD peaked at grade II.Figure 3. OS from initiation of therapy for aGVHD. Solid line repre-
sents survival in patients with an insignificant albumin decrease
(\0.5 g/dL), while dashed line represents survival in patients with an
albumin decrease of $0.5 g/dL.Serum Albumin and Mortality
Decreases in serum albumin concentration before
aGVHD onset also correlated with the risk of overall
mortality. Patients with a serum albumin decrease
from baseline of $0.5 g/dL before beginning
GVHD treatment showed an increased risk of mortal-
ity at 6 months after treatment initiation, persisting
through the follow-up period (Figure 3). At 6 months
after starting aGVHD treatment, OS was 83% versus
64% for patients without and with a pretreatment al-
bumin decrease of $0.5 g/dL, respectively (mortality
hazard ratio [HR]: 1.64, 95% confidence interval
[CI]: 1.2-2.2, P 5 .0009). This 19% absolute increase
in mortality was driven by nonrelapse deaths. Rates of
relapsed malignancy were similar in the 2 groups,
whereas NRM was significantly higher in the group
with a pretreatment albumin decrease (Figure 4).
The cumulative incidence of NRM in patients with
a$0.5 g/dL decrease in serum albumin concentration
was 27% at 6 months after starting treatment, com-
pared with 7% in the group without a substantial
pretreatment albumin decrease (HR: 2.01, 95% CI:
1.3-3.0, P5 .001). Rates of relapsed or progressivema-
lignancy at 6 months in the 2 groups were 27% amongFigure 2. ROC curves for serum albumin as a predictor of peak grade
3/4 aGVHD. Dashed line represents ROC of absolute serum albumin
concentration at initiation of systemic therapy for aGVHD. Solid line
represents ROC of change in serum albumin concentration from base-
line at initiation of systemic therapy for aGVHD.patients with an albumin decrease$0.5 g/dL and 25%
among those with stable albumin concentrations (HR:
1.25, 95% CI: 0.9-1.8, P5 .23). These figures include
progression rates of 9% and 4%, respectively, before
initiation of systemic therapy for aGVHD. A $0.5 g/
dL decrease from baseline serum albumin concentra-
tion predicted NRM at 6 months with a sensitivity of
64% and a specificity of 69%.Figure 4. Cumulative incidents of relapse (A) and NRM (B), stratified
by change in serum albumin at initiation of aGVHD treatment.
Figure 6. ROC curve for serum albumin decrease $0.5 g/dL alone
(solid line) and in combination with other clinical factors (dashed line)
in predicting progression to grade 3/4 aGVHD. The initial ROC curve
(solid line) has an area under the curve of 0.76. The incorporation of
other clinical variables (donor type, degree of HLA disparity, time to
aGVHD onset, patient age, and bilirubin, creatinine, and platelet count
at aGVHD treatment initiation) resulted in an ROC curve with an
area under the curve of 0.79 (dashed line).
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min concentration was an independent risk factor for
NRM.Lowbaseline albuminwas defined as a pretrans-
plantation albumin concentration of#3.0 g/dL, repre-
senting the lowest quartile of baseline values. Low
baseline serum albumin alone was not significantly
predictive of increased NRM (HR: 1.41, 95% CI:
0.9-2.3, P5 .16). Incorporating low baseline serum al-
bumin concentration into a predictive model for NRM
had essentially no effect on its association with albu-
min decrease (adjusted HR: 2.08, 95% CI: 1.4-3.1,
P 5 .0005).
We attempted to confirm that the increased risk of
NRM in patients with an albumin decrease was driven
primarily by aGVHD by retrospectively separating
these patients according to their ultimate peak
aGVHD grade. In patients whose aGVHD peaked at
grade II, pretreatment decreases in serum albumin
did not predict NRM. The association between
NRM and decreased albumin was confined solely to
those patients who developed grade III/IV aGVHD
(Figure 5). This finding supports the role of serum
albumin as a biomarker for midgut aGVHD and for
aGVHD-specific mortality, because the predictive
power of decreasing albumin as a biomarker of mortal-
ity derives entirely from its association with severe
midgut aGVHD.
Analysis of Covariates
We attempted to improve the predictive power of
falling serum albumin by incorporating other clinical
and laboratory parameters that might also predict
aGVHD severity or NRM. We analyzed data on do-
nor type (related versus unrelated), degree of HLA
disparity, time to aGVHD onset [17], patient age,
and total serum bilirubin, blood urea nitrogen, creat-
inine, and platelet count at aGVHD treatment initia-Figure 5. NRM from time of initiation of aGVHD treatment. ‘‘False-
positive’’ line represents patients with an albumin decrease of $0.5 g/
dL, but who did not progress to grade 3/4 aGVHD. Nonrelapse mortal-
ity is increased only in patients with an albumin decrease and severe
aGVHD, suggesting that the prognostic value of albumin decrease is
linked entirely to its ability to predict severe aGVHD.tion for the study cohort. Of these factors, only HLA
mismatch and time to aGVHD onset were weakly as-
sociated with progression to grade III/IV aGVHD.
When these factors were combined with serum albu-
min into a predictive model, the area under the ROC
curve improved slightly from 0.76 to 0.79 (Figure 6).
Thus, the inclusion of these additional clinical param-
eters did not substantially improve the prediction of
aGVHD severity.DISCUSSION
Decreases in serum albumin precede the clinical
onset of severe aGVHD and predict overall mortality
in patients treated for aGVHD after reduced-
intensity allogeneic HCT. Serum albumin measure-
ment is standardized, inexpensive, and widely available
with rapid turnaround. This biomarker can readily be
applied to aid real-time clinical decision making:
When a patient develops aGVHD requiring systemic
treatment, serum albumin concentration can be mea-
sured and compared with the pretransplantation base-
line value. If the serum albumin concentration has
decreased by $0.5 g/dL from baseline, then the
patient is at increased risk of severe midgut GVHD
and NRM. Because this information is available at
the time of treatment initiation, high-risk patients
could be stratified to receive more aggressive immu-
nosuppressive therapy up front, ideally suppressing
graft-versus-host reactions before irreversible muco-
sal injury occurs.
Serum albumin concentration is influenced by nu-
merous factors, including nutritional status and he-
patic synthetic function. Hypoalbuminemia resulting
from decreased protein synthesis develops gradually,
because the half-life of serum albumin is
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cline seen in this patient cohort is characteristic of
rapid protein loss from the midgut, and its temporal
association with clinical aGVHD onset supports
a pathophysiologic link between the 2. Mean albumin
levels remained constant in patients with grade II
aGVHD, suggesting that neither the actual transplant
process nor upper gut involvement with aGVHD pro-
duces significant protein loss or hypoalbuminemia.
In 1983, Weisdorf et al. [10] documented gut pro-
tein loss as an early, often preclinical phenomenon in
patients with aGVHD after myeloablative allogeneic
HCT. In that study, fecal levels of a1-antitrypsin
increased modestly after myeloablative conditioning,
but returned to baseline in patients without aGVHD.
In contrast, patients with midgut aGVHD showed
persistent and substantial increases in fecal a1-
antitrypsin excretion, suggesting ongoing protein
loss. Gut involvement with aGVHD early after mye-
loablative HCT is characterized histologically by scat-
tered apoptotic cells in the mucosal crypts and
radiologically by mucosal edema [19,20]. Protein-
losing enteropathy does not require ulceration or de-
nudation of intestinal epithelium, but likely occurs
through leaky epithelial tight junctions [21]. Data
from studies of fecal a1-antitrypsin excretion and
from the current study suggest that protein-losing en-
teropathy in aGVHD is a reflection of the cytokine
milieu in the midgut mucosa. Tight junctions (zonula
occludens) in midgut epithelium regulate the transit of
lamina propria protein into the lumen and the translo-
cation of luminal bacteria and endotoxin into the
lamina propria [21].
Although peak aGVHD grade can be retrospec-
tively correlated with NRM, GVHD grading is only
marginally useful as a prospective tool to predict out-
come at the time of disease onset [22,23]. Better
predictors of clinical outcome with aGVHD include
the area under a disease activity curve [23], failure of
initial glucocorticoid treatment, and markers of gut
mucosal necrosis after diagnosis [24]. Because these
parameters are not available until after the clinical on-
set of aGVHD, diagnostic and prognostic tests that
can be employed before or at the clinical onset of
aGVHD are needed. Decreasing serum albumin ap-
pears to possess the characteristics of such a test.
These findings, along with work on other aGVHD
biomarkers, imply that initial therapy for aGVHD
might move from a reactive to a preemptive approach,
just as therapy for cytomegalovirus reactivation after
HCT has moved to a preemptive approach based on
detection of cytomegalovirus DNA. This hypothesis
lends itself readily to evaluation in prospective
clinical trials.
Preemptive approaches to aGVHD therapy are
hampered, however, by the relatively low prevalence
of severe aGVHD [9], which limits the positive predic-tive value of even highly sensitive and specific diagnos-
tic tests. In this study cohort, 19%of patients requiring
systemic therapy for aGVHD progressed to severe
aGVHD. Given this prevalence, the sensitivity and
specificity of serum albumin (69% and 73%, respec-
tively) translate into a positive predictive value of
37% and a negative predictive value of 91% for the de-
velopment of severe (rather than grade II) aGVHD.
These figures highlight the difficulty of accurately pre-
dicting a low-prevalence condition such as severe
aGVHD, a difficulty that is common to all published
aGVHD biomarkers. In this regard, an advantage of
serum albumin measurement is that it can be applied
at the time of treatment initiation for aGVHD, rather
than in asymptomatic patients without active GVHD.
Thus, even ‘‘false-positive’’ patients (those whose
aGVHD is destined to peak at grade II) require some
level of aGVHD therapy, and the hazard of overtreat-
ment can be minimized.
NRM andOS are well-defined endpoints with clear
clinical relevance, and an ideal biomarker would predict
not only peak aGVHD grade (which correlates only
loosely with clinical outcome) but also NRM and OS.
In our cohort, albumin decrease predicts a 20% abso-
lute increase in risk ofNRMat 6months from initiation
of aGVHD treatment. The proteomic panel described
by Paczesny et al. [6] similarly identifies a high-risk
group of patients with a 15% absolute increase in risk
of mortality at 3.5 years after HCT. Nishiwaki et al.
[25] recently described macrophage infiltration into
skin lesions as a predictor of severe aGVHD and mor-
tality, with reported sensitivities of 25% to 44% and
specificities of 70% to 87%. A sophisticated proteomic
assay developed by Mischak-Weissinger et al. [5] pre-
dicts the onset of aGVHD with a reported sensitivity
and specificity of 76% and 85%, respectively, although
data on prediction of severe aGVHD and mortality
were not given. Thus, the performance characteristics
of serum albumin as an aGVHD biomarker are similar,
and in some cases superior, to those of other recently
reported approaches. In contrast to these other ap-
proaches, serum albumin measurement has the added
advantages of simplicity, low cost, rapid turnaround,
and widespread availability.
An important limitation is that our findings apply
only to patients conditioned with reduced-intensity
regimens that do not cause appreciable regimen-
related mucosal injury. High-dose chemotherapy or
radiation may damage the intestinal mucosa, causing
protein loss that overlaps with that caused by aGVHD
and obscuring the value of albumin as a GVHD-
specific biomarker. Thus, our current data cannot be
extrapolated to support the use of albumin as a bio-
marker of aGVHD in patients receiving myeloablative
conditioning.
In summary, decreases in serum albumin before
aGVHD onset have substantial predictive value as
1600 Biol Blood Marrow Transplant 17:1594-1601, 2011A. R. Rezvani et al.a biomarker for aGVHD severity and death in pa-
tients undergoing reduced-intensity allogeneic
HCT. A simple comparison of serum albumin at the
time of aGVHD treatment initiation to a patient’s
baseline value can identify patients with a 20% abso-
lute increase in the risk of death at 6 months. This in-
creased risk appears to be driven entirely by aGVHD,
making this high-risk group a logical target for pre-
emptive intensification of aGVHD therapy. Because
many preemptive interventions against aGVHD carry
significant risk to the patient, it may be necessary to
improve the positive predictive value of decreasing se-
rum albumin by incorporating other biomarkers. Al-
though the search for an ideal aGVHD biomarker
remains incomplete, we believe that changes in serum
albumin provide a simple, novel, and biologically based
addition to the predictive tools available to transplant
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